托法替布在溃疡性结肠炎真实世界队列中的安全性
该研究在美國6个医疗中心纳入260例溃疡性结肠炎患者,随访中位6个月,评估托法替布不良事件发生率。41例(15.7%)发生不良事件,任何不良事件发生率为27.2/100患者年,严重不良事件发生率为10.0/100患者年,5例发生带状疱疹、2例发生静脉血栓栓塞(均接受10 mg每日两次)。结论认为真实世界安全信号与临床试验相似,支持诱导缓解后降阶梯剂量以减少不良事件风险。
要点
- 260例溃疡性结肠炎患者中41例(15.7%)发生不良事件,任何不良事件发生率为27.2/100患者年。
- 严重不良事件15例(占不良事件的36.6%),严重不良事件发生率为10.0/100患者年。
- 5例发生带状疱疹、2例发生静脉血栓栓塞,均在接受10 mg每日两次托法替布的患者中。
核心结论
- 真实世界托法替布安全信号与临床试验相似,约16%患者报告不良事件。
- 带状疱疹和静脉血栓栓塞发生于接受10 mg每日两次托法替布的患者。
- 结果支持诱导治疗后降阶梯剂量以减少不良事件风险。
研究设计与样本
- 研究为托法替布真实世界结局 consortium 研究,在美国6个医疗中心纳入260例溃疡性结肠炎患者。
- 患者随访中位6个月(四分位距2.7-11.5个月)。
- 不良事件通过标准化数据收集工具在研究启动前及第8、16、26、39、52周采集。
- 严重不良事件定义为危及生命或导致住院、残疾或停药。
- 采用逻辑回归分析不良事件危险因素。
主要发现
- 41例患者(15.7%)发生不良事件,其中大多数为感染(N=13;5.0%)。
- 任何不良事件发生率为27.2(95% CI 24.4-30.7)/100患者年随访。
- 严重不良事件15例(占不良事件的36.6%),12例患者(队列的4.6%)因不良事件停用托法替布。
- 严重不良事件发生率为10.0(95% CI 8.9-11.2)/100患者年随访。
- 5例患者发生带状疱疹感染,2例发生静脉血栓栓塞,均在接受10 mg每日两次托法替布的患者中。
关键数值与推荐
- 任何不良事件发生率为27.2(95% CI 24.4-30.7)/100患者年随访。
- 严重不良事件发生率为10.0(95% CI 8.9-11.2)/100患者年随访。
- 不良事件发生于41/260例患者(15.7%),感染13例(5.0%)。
- 严重不良事件15例(占不良事件的36.6%),12例(4.6%)因不良事件停药。
- 带状疱疹5例、静脉血栓栓塞2例,均在接受10 mg每日两次托法替布的患者中。
临床怎么用
- 作者认为结果支持诱导治疗后降阶梯剂量以减少不良事件风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Adverse events (AEs) including reactivation of herpes zoster (HZ) and venous thromboembolism (VTE) have been reported from clinical trials of tofacitinib in ulcerative colitis (UC). We investigated the incidence rates of AEs in a real-world study of UC patients given tofacitinib. METHODS: We collected data from 260 patients with UC in the Tofacitinib Real-world Outcomes in Patients with ulceratIve colitis and Crohn's disease consortium study, performed at 6 medical centers in the United States. Patients were followed up for a median of 6 months (interquartile range, 2.7-11.5 mo). AEs were captured using a standardized data collection instrument before study initiation and at weeks 8, 16, 26, 39, and 52. Serious AEs were defined as life-threatening or resulting in a hospitalization, disability, or discontinuation of therapy. Logistic regression was performed to examine risk factors for AEs. RESULTS: AEs occurred in 41 patients (15.7%); most were infections (N = 13; 5.0%). The incidence rate of any AE was 27.2 (95% CI, 24.4-30.7 per 100 patient-years of follow-up evaluation). Fifteen were serious AEs (36.6% of AEs), and tofacitinib was discontinued for 12 patients (4.6% of cohort). The incidence rates of serious AEs was 10.0 (95% CI, 8.9-11.2 per 100 patient-years of follow-up evaluation). Five patients developed HZ infection and 2 developed VTE (all receiving 10 mg tofacitinib, twice per day). CONCLUSIONS: Real-world safety signals for tofacitinib are similar to those for clinical trials, with AEs reported from almost 16% of patients. HZ infection and VTE occurred in patients receiving 10 mg tofacitinib twice per day. These results support dose de-escalation after induction therapy, to reduce the risk of AEs.
引用
- Deepak P, Alayo QA, Khatiwada A, et al. Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020. PMID: 32629130. doi:10.1016/j.cgh.2020.06.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。